,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationMean,recommendationKey,totalCash,totalCashPerShare,totalDebt,quickRatio,currentRatio,returnOnAssets,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,4960 Peachtree Industrial Boulevard,Suite 240,Norcross,GA,30071,United States,678 620 3186,https://galectintherapeutics.com,Biotechnology,Healthcare,"Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.",12,"{'maxAge': 1, 'name': 'Mr. Joel  Lewis', 'age': 52, 'title': 'Pres, CEO & Director', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 870664, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.95,1.95,1.76,1.95,1.95,1.95,1.76,1.95,0.0,1.330912,-2.5882351,116868,116868,60062,52960,52960,1.7,1.87,1200,1100,104864848,1.02,2.47,1.615,1.58695,0.0,0.0,USD,161749392,0.0,42209260,59582300,2024586,2037718,1690761600,1693440000,0.034,0.2909,0.120799996,43.94,0.3747,-0.896,1672444800,1703980800,1688083200,-39984000,-0.68,-0.68,1:6,1332460800,NCM,EQUITY,GALT,GALT,Galectin Therapeutics Inc.,Galectin Therapeutics Inc.,1031146200,America/New_York,EDT,-14400000,1.76,2.0,buy,17966000,0.302,61297000,1.805,1.956,-1.03607,-23144876,-36212000,0.0,0.0,0.0,USD,
1,4960 Peachtree Industrial Boulevard,Suite 240,Norcross,GA,30071,United States,678 620 3186,https://galectintherapeutics.com,Biotechnology,Healthcare,"Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.",12,"{'maxAge': 1, 'name': 'Mr. Jack W. Callicutt CPA, CPA', 'age': 55, 'title': 'CFO, Treasurer & Corp. Sec.', 'yearBorn': 1967, 'fiscalYear': 2016, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.95,1.95,1.76,1.95,1.95,1.95,1.76,1.95,0.0,1.330912,-2.5882351,116868,116868,60062,52960,52960,1.7,1.87,1200,1100,104864848,1.02,2.47,1.615,1.58695,0.0,0.0,USD,161749392,0.0,42209260,59582300,2024586,2037718,1690761600,1693440000,0.034,0.2909,0.120799996,43.94,0.3747,-0.896,1672444800,1703980800,1688083200,-39984000,-0.68,-0.68,1:6,1332460800,NCM,EQUITY,GALT,GALT,Galectin Therapeutics Inc.,Galectin Therapeutics Inc.,1031146200,America/New_York,EDT,-14400000,1.76,2.0,buy,17966000,0.302,61297000,1.805,1.956,-1.03607,-23144876,-36212000,0.0,0.0,0.0,USD,
2,4960 Peachtree Industrial Boulevard,Suite 240,Norcross,GA,30071,United States,678 620 3186,https://galectintherapeutics.com,Biotechnology,Healthcare,"Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.",12,"{'maxAge': 1, 'name': 'Dr. Pol F. Boudes M.D., Ph.D.', 'age': 65, 'title': 'Chief Medical Officer', 'yearBorn': 1957, 'fiscalYear': 2022, 'totalPay': 720637, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.95,1.95,1.76,1.95,1.95,1.95,1.76,1.95,0.0,1.330912,-2.5882351,116868,116868,60062,52960,52960,1.7,1.87,1200,1100,104864848,1.02,2.47,1.615,1.58695,0.0,0.0,USD,161749392,0.0,42209260,59582300,2024586,2037718,1690761600,1693440000,0.034,0.2909,0.120799996,43.94,0.3747,-0.896,1672444800,1703980800,1688083200,-39984000,-0.68,-0.68,1:6,1332460800,NCM,EQUITY,GALT,GALT,Galectin Therapeutics Inc.,Galectin Therapeutics Inc.,1031146200,America/New_York,EDT,-14400000,1.76,2.0,buy,17966000,0.302,61297000,1.805,1.956,-1.03607,-23144876,-36212000,0.0,0.0,0.0,USD,
3,4960 Peachtree Industrial Boulevard,Suite 240,Norcross,GA,30071,United States,678 620 3186,https://galectintherapeutics.com,Biotechnology,Healthcare,"Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.",12,"{'maxAge': 1, 'name': 'Robert  Tritt', 'title': 'Gen. Counsel', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.95,1.95,1.76,1.95,1.95,1.95,1.76,1.95,0.0,1.330912,-2.5882351,116868,116868,60062,52960,52960,1.7,1.87,1200,1100,104864848,1.02,2.47,1.615,1.58695,0.0,0.0,USD,161749392,0.0,42209260,59582300,2024586,2037718,1690761600,1693440000,0.034,0.2909,0.120799996,43.94,0.3747,-0.896,1672444800,1703980800,1688083200,-39984000,-0.68,-0.68,1:6,1332460800,NCM,EQUITY,GALT,GALT,Galectin Therapeutics Inc.,Galectin Therapeutics Inc.,1031146200,America/New_York,EDT,-14400000,1.76,2.0,buy,17966000,0.302,61297000,1.805,1.956,-1.03607,-23144876,-36212000,0.0,0.0,0.0,USD,
4,4960 Peachtree Industrial Boulevard,Suite 240,Norcross,GA,30071,United States,678 620 3186,https://galectintherapeutics.com,Biotechnology,Healthcare,"Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.",12,"{'maxAge': 1, 'name': 'Mr. Jeff  Katstra', 'title': 'Head of CMC & Pharmaceutical Devel.', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.95,1.95,1.76,1.95,1.95,1.95,1.76,1.95,0.0,1.330912,-2.5882351,116868,116868,60062,52960,52960,1.7,1.87,1200,1100,104864848,1.02,2.47,1.615,1.58695,0.0,0.0,USD,161749392,0.0,42209260,59582300,2024586,2037718,1690761600,1693440000,0.034,0.2909,0.120799996,43.94,0.3747,-0.896,1672444800,1703980800,1688083200,-39984000,-0.68,-0.68,1:6,1332460800,NCM,EQUITY,GALT,GALT,Galectin Therapeutics Inc.,Galectin Therapeutics Inc.,1031146200,America/New_York,EDT,-14400000,1.76,2.0,buy,17966000,0.302,61297000,1.805,1.956,-1.03607,-23144876,-36212000,0.0,0.0,0.0,USD,
5,4960 Peachtree Industrial Boulevard,Suite 240,Norcross,GA,30071,United States,678 620 3186,https://galectintherapeutics.com,Biotechnology,Healthcare,"Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.",12,"{'maxAge': 1, 'name': 'Ms. Beth  Knowles', 'title': 'Exec. Assistant & Officer Mang.', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.95,1.95,1.76,1.95,1.95,1.95,1.76,1.95,0.0,1.330912,-2.5882351,116868,116868,60062,52960,52960,1.7,1.87,1200,1100,104864848,1.02,2.47,1.615,1.58695,0.0,0.0,USD,161749392,0.0,42209260,59582300,2024586,2037718,1690761600,1693440000,0.034,0.2909,0.120799996,43.94,0.3747,-0.896,1672444800,1703980800,1688083200,-39984000,-0.68,-0.68,1:6,1332460800,NCM,EQUITY,GALT,GALT,Galectin Therapeutics Inc.,Galectin Therapeutics Inc.,1031146200,America/New_York,EDT,-14400000,1.76,2.0,buy,17966000,0.302,61297000,1.805,1.956,-1.03607,-23144876,-36212000,0.0,0.0,0.0,USD,
